NEW YORK, Sept. 26 - Dresdner Kleinwort Wasserstein has begun covering a handful of “special niche” genomic and proteomic companies, the financial company said on Wednesday.

The coverage, which will be led by analyst Charles C. Duncan, will include Celgene, CuraGen, Exelixis, Human Genome Sciences, Millennium Pharmaceuticals, Myriad Genetics, Tularik, and Vertex Pharmaceuticals. These all were rated a “Buy,” the company said in a statement. Two more companies, Celera Genomics and Sangamo BioSciences, were rated an “Add.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.